Regeneron Pharmaceuticals (REGN) Stock Price, Quote & News

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul...

Industry: Biotechnology

Sector: Healthcare

Phone: 914 847 7000

Website: www.regeneron.com

Address:

777 Old Saw Mill River Road, Tarrytown, United States

BioTechHealthX Jul. 4 at 12:45 PM

$REGN $VRTX $NVO $ABBV $LLY From obesity drugs and diabetes treatments to CRISPR gene editing, mRNA cancer vaccines, biologics, and rare disease therapies, these 5 biotech stocks could be among the most exciting healthcare stocks to watch in today’s market. https://biotechhealthx.com/biotech-news/5-biotech-stocks-that-could-turn-medicine-into-wall-streets-next-gold-rush/

0 · Reply

StreakGeek Jul. 2 at 5:47 PM

$JNJ $MSCI $REGN $DVA dmas

0 · Reply

Whiskeyunderthebed Jul. 2 at 2:26 PM

$REGN Money flow and sector rotation is coming in finally.

1 · Reply

NewEarth Jul. 2 at 12:15 PM

$NTLA $PRME $CRBU $BEAM $REGN Hahahaha

0 · Reply

DidYouReadThis Jun. 30 at 11:33 PM

$OTLK Pausing emotions and hype, what’s your most #realistic #potential #buyout target after 7/29/26 potential FDA Approval for $OTLK’s wet AMD potential blockbuster opthalmic bevacizumab? $PFE $MRK $REGN

2 · Reply

DidYouReadThis Jun. 30 at 10:46 PM

$OTLK $REGN $PFE $ON

0 · Reply

prismmarketview Jun. 30 at 1:45 PM

$LLY (NYSE), $REGN (NASDAQ), $AMRX (NYSE), Kyowa Kirin (TYO:4151) and others just got tapped for the FDA’s new PreCheck pilot—designed to fast‑track and de‑risk US drug‑plant approvals while shoring up the domestic supply chain. Early inclusion turns these facilities into strategic assets, not just capex line items, and positions the cohort as reference cases for future manufacturing policy. #LLY #REGN #AMRX #KyowaKirin #FDA #pharma #DrugManufacturing #MadeInUSA #biotech https://x.com/PrismMarketView/status/2071953066430009460?s=20

0 · Reply

free2dream Jun. 30 at 12:57 PM

$SNDK sandisk is worth 6 Regenerons on same sales. IT IS ABSURD . $SNDQ all the way, make money when this pig colapses $REGN

0 · Reply

inspector_gadget86 Jun. 29 at 10:58 PM

$REGN $LLY $AMRX $DJT Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s PreCheck pilot program

0 · Reply

free2dream Jun. 29 at 7:42 PM

$SPY $SNDK market cap is 6x $REGN on roughly same sales. ABSOLUTELY IDIOTIC

0 · Reply

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

LLY REGN

Jun 29, 2026, 2:50 PM EDT - 5 days ago

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

LLY REGN

Jun 25, 2026, 4:05 PM EDT - 8 days ago

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

REGN

Jun 22, 2026, 7:00 AM EDT - 12 days ago

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

REGN

Jun 12, 2026, 10:30 AM EDT - 22 days ago

Regeneron Pharmaceuticals Transcript: AGM 2026

Jun 12, 2026, 10:30 AM EDT - 22 days ago

Regeneron Pharmaceuticals Slides: FY 2026

Jun 8, 2026, 2:00 PM EDT - 26 days ago

Regeneron Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 7:00 AM EDT - 4 weeks ago

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

REGN

May 28, 2026, 4:00 PM EDT - 5 weeks ago

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

REGN

May 25, 2026, 11:31 AM EDT - 5 weeks ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

REGN

May 22, 2026, 7:00 AM EDT - 6 weeks ago

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

REGN

May 21, 2026, 5:01 PM EDT - 6 weeks ago

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

REGN

May 18, 2026, 3:25 PM EDT - 6 weeks ago

Regeneron stock drops double digits on oncology trial failure

REGN

May 18, 2026, 7:28 AM EDT - 6 weeks ago

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda

REGN

May 18, 2026, 7:04 AM EDT - 6 weeks ago

Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints

REGN

May 18, 2026, 7:00 AM EDT - 6 weeks ago

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

REGN

May 18, 2026, 7:00 AM EDT - 6 weeks ago

Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

REGN

May 18, 2026, 5:57 AM EDT - 6 weeks ago

Regeneron drops after skin cancer treatment misses late-stage trial goal

REGN

May 15, 2026, 8:19 PM EDT - 7 weeks ago

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

REGN

May 15, 2026, 5:56 PM EDT - 7 weeks ago

UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

REGN

May 15, 2026, 4:27 PM EDT - 7 weeks ago

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

REGN

May 12, 2026, 1:00 PM EDT - 7 weeks ago

Regeneron Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 7:00 AM EDT - 2 months ago

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

REGN

May 5, 2026, 7:00 AM EDT - 2 months ago

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

REGN

Apr 29, 2026, 8:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Quarterly report: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 7:43 AM EDT - 2 months ago

Regeneron beats quarterly results estimates on strong Dupixent demand

REGN

Apr 29, 2026, 6:30 AM EDT - 2 months ago

Regeneron Reports First Quarter 2026 Financial and Operating Results

REGN

Apr 24, 2026, 2:37 PM EDT - 2 months ago

Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss

REGN

Apr 24, 2026, 10:30 AM EDT - 2 months ago

Regeneron CEO on deal with Trump admin to lower drug prices

REGN

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Regeneron Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Regeneron Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 3:46 PM EDT - 2 months ago

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

REGN

Apr 23, 2026, 3:40 PM EDT - 2 months ago

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

REGN

Apr 23, 2026, 3:21 PM EDT - 2 months ago

Regeneron to offer prescriptions at most favored nation prices, Trump says

REGN

Apr 23, 2026, 1:42 PM EDT - 2 months ago

FDA Approves First-Ever Gene Therapy to Restore Hearing

REGN

Apr 23, 2026, 12:45 PM EDT - 2 months ago

FDA approves Regeneron's gene therapy for inherited deafness

REGN

Apr 23, 2026, 12:40 PM EDT - 2 months ago

Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

REGN

Apr 23, 2026, 12:00 PM EDT - 2 months ago

White House to announce drug pricing deal with Regeneron, source says

REGN

Apr 22, 2026, 5:30 PM EDT - 2 months ago

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

REGN

Apr 22, 2026, 5:30 PM EDT - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

REGN SNY

Apr 22, 2026, 8:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Transcript: Status update

Apr 22, 2026, 8:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Press release: Status update

Apr 22, 2026, 8:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Slides: Status update

Apr 21, 2026, 10:30 AM EDT - 2 months ago

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

REGN

Apr 20, 2026, 4:05 PM EDT - 2 months ago

Regeneron Announces Investor Conference Presentations

REGN

Apr 13, 2026, 6:30 AM EDT - 2 months ago

Regeneron and Telix Announce Strategic Radiopharma Collaboration

REGN

Apr 13, 2026, 1:00 AM EDT - 2 months ago

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

REGN

Apr 13, 2026, 1:00 AM EDT - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

REGN SNY

Apr 2, 2026, 4:30 PM EDT - 3 months ago

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

REGN

Apr 2, 2026, 4:30 PM EDT - 3 months ago

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

REGN

Apr 2, 2026, 2:27 PM EDT - 3 months ago

Regeneron says it expects to avoid new US pharma tariffs

REGN

Apr 2, 2026, 12:00 PM EDT - 3 months ago

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

REGN

BioTechHealthX Jul. 4 at 12:45 PM

0 · Reply

StreakGeek Jul. 2 at 5:47 PM

$JNJ $MSCI $REGN $DVA dmas

0 · Reply

Whiskeyunderthebed Jul. 2 at 2:26 PM

$REGN Money flow and sector rotation is coming in finally.

1 · Reply

NewEarth Jul. 2 at 12:15 PM

$NTLA $PRME $CRBU $BEAM $REGN Hahahaha

0 · Reply

DidYouReadThis Jun. 30 at 11:33 PM

2 · Reply

DidYouReadThis Jun. 30 at 10:46 PM

$OTLK $REGN $PFE $ON

0 · Reply

prismmarketview Jun. 30 at 1:45 PM

0 · Reply

free2dream Jun. 30 at 12:57 PM

$SNDK sandisk is worth 6 Regenerons on same sales. IT IS ABSURD . $SNDQ all the way, make money when this pig colapses $REGN

0 · Reply

inspector_gadget86 Jun. 29 at 10:58 PM

0 · Reply

free2dream Jun. 29 at 7:42 PM

$SPY $SNDK market cap is 6x $REGN on roughly same sales. ABSOLUTELY IDIOTIC

0 · Reply

LiveSquawk Jun. 29 at 6:54 PM

Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities – CNBC $LLY $REGN https://www.cnbc.com/2026/06/29/eli-lilly-regeneron-in-fda-precheck-manufacturing-program.html

0 · Reply

BioTechHealthX Jun. 28 at 7:23 AM

$REGN Regeneron Pharmaceuticals Inc. (REGN) is back in the spotlight after regulatory applications for cemdisiran were accepted, giving investors another reason to watch this major biotech stock. https://biotechhealthx.com/biotech-news/is-regeneron-pharmaceuticals-regn-still-a-smart-biotech-stock-to-buy/

0 · Reply

BioTechHealthX Jun. 28 at 6:11 AM

$REGN $JNJ $LLY $PFE $SYK Artificial intelligence is no longer just a tech story. These healthcare stocks are using AI, automation, digital platforms, and advanced medical tools to improve clinical workflows, diagnostics, drug development, and patient outcomes. https://biotechhealthx.com/biotech-news/top-5-ai-powered-healthcare-stocks-that-can-make-you-rich/

0 · Reply

topstockalerts Jun. 27 at 2:15 AM

Healthcare stocks attracted strong investor demand this week as money rotated out of technology shares, pushing AbbVie, Eli Lilly and Johnson & Johnson to record closing highs. The sector benefited from its defensive characteristics and confidence in the long-term growth prospects of leading pharmaceutical companies. AbbVie's shares received an additional boost after the company announced plans to acquire Apogee Therapeutics, strengthening its drug development pipeline. According to RBC Capital Markets, AbbVie, Eli Lilly and Johnson & Johnson have largely avoided the operational setbacks that forced several competitors to restructure, while making strategic acquisitions that enhance future growth opportunities. Other biopharmaceutical companies, including Regeneron, Sanofi, Moderna and Absci, also advanced, lifting healthcare-focused ETFs as investors sought stability amid weakness in technology stocks and growing uncertainty around AI-related valuations. $ABBV $APGE $REGN $SNY $LLY

0 · Reply

Iwannagofast1 Jun. 26 at 6:58 PM

$REGN Waiting for under $500 again

1 · Reply

DidYouReadThis Jun. 26 at 6:13 PM

Do you think $OTLK will go past a 7 billion market cap within 7 years? $REGN $PFE $MCK

0 · Reply

Orbit100 Jun. 26 at 5:27 PM

$REGN ISS-EVA official declars REGN is a strong buy today.

0 · Reply

free2dream Jun. 26 at 1:40 PM

$SPY $LITE IS STILL BIGGER THAN $REGN . Let that nonsense sink in.

0 · Reply

BillionerOfKing Jun. 25 at 10:38 PM

$REGN Current Stock Price: $619.90 Contracts to trade: $620.0 REGN Jun 26 2026 Call Entry: $2.85 Exit: $4.74 ROI: 66% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

DidYouReadThis Jun. 25 at 7:47 PM

Good luck $OTLK on the 7/29/26 PDUFA for opthalmic bevacizumab for wet AMD! $REGN

0 · Reply

TopTierNewswire Jun. 25 at 5:26 AM

Top AI Long Candidates from Top Tier Newswire right now: $VRNS $REGN $ABBV $DFTX - Major Biotech sector strength and most I've seen fill the dashboard as top picks!

0 · Reply

DidYouReadThis Jun. 23 at 5:39 PM

Good luck $REGN! <3 <3 <3

0 · Reply

Market Cap	69.17B
Revenue (ttm)	14.34B
Net Income (ttm)	4.50B
EPS (ttm)	N/A
PE Ratio	16.82
Forward PE	16.69
Profit Margin	31.41%
Debt to Equity Ratio	0.06

Volume	1,071,600
Avg Vol	1,087,632
Day's Range	N/A - N/A
Shares Out	105.72M
Stochastic %K	99%
Beta	0.24
Analysts	Strong Sell
Price Target	$834.72